Mobile

Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study

Update Il y a 4 ans
Reference: EUCTR2008-005557-38

Woman Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

to evaluate the tolerability and safety of once daily oral Vandetanib 100 mg when added to standard therapy (pegliposomal doxorubicin 50 mg/m2 iv every 4 weeks) compared to standard therapy alone (pegliposomal doxorubicin 50 mg/m2 iv every 4 weeks)

Inclusion criteria

  • Ovarian Cancer

Links